Amerika Serikat - Inggris - NLM (National Library of Medicine)

schuyler llc - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 0.57 mg in 1 ml - indications : for the treatment of infected superficial lesions in dogs caused by bacteria sensitive to gentamicin. contraindications : if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

vedco - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 3 mg in 1 ml - indications: gentamicin sulfate with betamethasone valerate otic solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin. contraindications: if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. this preparation should not be used in conditions where corticosteroids are contraindicated. do not administer parenteral corticosteroids during treatment with gentamicin sulfate with betamethasone valerate otic solution.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

mwi - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 3 mg in 1 ml - indications: gentamicin sulfate with betamethasone valerate otic solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin. contraindications: if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. this preparation should not be used in conditions where corticosteroids are contraindicated. do not administer parenteral corticosteroids during treatment with gentamicin sulfate with betamethasone valerate otic solution.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

clipper distributing company llc - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 3 mg in 1 ml - indications: gentamicin sulfate with betamethasone valerate otic solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin. contraindications: if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. this preparation should not be used in conditions where corticosteroids are contraindicated. do not administer parenteral corticosteroids during treatment with gentamicin sulfate with betamethasone valerate otic solution.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

henry schein animal health - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 3 mg in 1 ml - indications: gentamicin sulfate with betamethasone valerate otic solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin. contraindications: if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. this preparation should not be used in conditions where corticosteroids are contraindicated. do not administer parenteral corticosteroids during treatment with gentamicin sulfate with betamethasone valerate otic solution.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

med-pharmex, inc - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m), clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65) - gentamicin-betamethasone-clotrimazole ointment is indicated for the treatment of canine acute and chronic otitis externa associated with yeast (malassezia pachydermatis , formerly pityrosporum canis ) and/or bacteria susceptible to gentamicin. if hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. do not use in dogs with known perforation of eardrums.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

covetrus north america - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - indications: gentamicin sulfate with betamethasone valerate otic solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin. contraindications: if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. this preparation should not be used in conditions where corticosteroids are contraindicated. do not administer parenteral corticosteroids during treatment with gentamicin sulfate with betamethasone valerate otic solution.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 ml - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. hypothalamic-pituitary-adrenal (hpa) axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere with the growth and development of children.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

sti pharma llc - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.0 mg in 1 ml - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of cortico-steroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. hypothalamic-pituitary-adrenal (hpa) axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topic